- Press Release Distribution

Paradox lost: Speedier heart attack treatment saves more lives after all, study suggests

Because more and sicker patients now get emergency angioplasty and stents, population-wide results look puzzling -- but new analysis clears confusion

Paradox lost: Speedier heart attack treatment saves more lives after all, study suggests
( ANN ARBOR, Mich. -- A national effort to shave minutes off emergency heart attack treatment time has increased the chance that each patient will survive, a new study suggests. But yet the survival rate for all patients put together hasn't budged.

It seems like a paradox. But wait, say the authors of the new report: the paradox vanishes with more detailed analysis of exactly who has been getting this treatment.

Far more people are getting emergency angioplasty and stents for heart attacks now than before. That number now includes more people with more complicated health issues that can put them at higher risk for dying in the hospital or soon after.

By comparing individual results and population-level results in a statistical model, the authors of a new paper in the journal Lancet burst the paradoxical bubble. They find that the massive effort by medical teams, hospitals and ambulance companies to reduce the time it takes to deliver treatment has indeed appeared to pay off.

The authors, from the University of Michigan Medical School, Yale University Medical School and other institutions, say their results build upon, rather than contradict, previous key findings. That study found that death rates had not budged, or had gone up, even as treatment time went down.

Thanks to the "open science" movement and the ability to study the same data that others have looked at, but with different tools, the researchers could look deeper into the topic. Their work adds important perspective to understanding the effect of cutting "door-to-balloon time" in primary percutaneous coronary intervention, or pPCI, for patients with ST-elevation myocardial infarction (STEMI), or heart attacks causing a prolonged blockage of blood supply to the heart muscle.

The new paper draws on data from 150,116 pPCI procedures performed in 423 hospitals between 2005 and 2011, including six-month follow-up data in an important subgroup. The data come from the National Cardiovascular Data Registry.

In that seven-year period, the number of pPCI procedures rose 55.4 percent - and the average time between a patient's arrival and the inflation of a tiny balloon to start reopening their blocked blood vessels went down from 86 minutes to 63 minutes.

"This is a big change in a relatively short time, and the result of many people working collaboratively together," says Brahmajee Nallamothu, M.D., MPH, first author and an interventional cardiologist at the U-M Health System. "Treating more patients, with higher risk, over time appears to be why mortality hasn't gone down with door-to-balloon time."

"In the past decade, entire systems of care have been reorganized both inside and outside the hospital around treating heart attack patients with pPCI more rapidly, and seeing the entire process as a medical emergency," continues Nallamothu, an associate professor of internal medicine who cares for patients at U-M's Frankel Cardiovascular Center. "So, people who now receive this procedure are fundamentally different than even a few years before. We now have the ability to perform these procedures on more patients."

Plus, because of the increased effort by ambulance crews to get more patients to a hospital and diagnose their heart attack before they arrive, more patients are surviving long enough to reach the hospital and get triaged for pPCI than ever did before.

And all of this taken together, he and his colleagues found, is where the seeming paradox arose when researchers studied the overall death risk of pPCI patients across the population. Despite years of reduced door-to-balloon times, mortality rates weren't going down - and even appeared to be going up. Even in the new paper, the authors report that this was the case when they looked at mortality across the study population.

That's why the new analysis, which uses a multilevel model and adjusts for individual patient risk factors, was important to do, says senior author Harlan Krumholz, M.D., S.M., of Yale.

"This settles some of the concern that shorter times were not benefiting patients and makes clear that advances in quality of care in terms of timely treatment is very importantly linked with survival after heart attacks," says Krumholz, who is the Harold H. Hines, Jr. Professor of Medicine at Yale and director of the Yale-New Haven Hospital Center for Outcomes Research and Evaluation.

The authors say the new findings don't answer the question of whether the resources poured into reducing door-to-balloon time have "paid off" in terms of the value of lives saved, nor the impact of the cost of false activations of hospitals' pPCI teams and facilities when a patient turns out not to be suffering a STEMI. Also unanswered: whether continued reductions in door-to-balloon time will continue to pay off in reduce individual death risk.

But the new analysis shows the potential danger of taking population data as the last word on an issue, especially when the cohort of people in a given population has grown or changed over time. The population-level analysis published in the New England Journal of Medicine last year showed unchanged mortality in pPCI patients from 2005 to 2009 using the same data source as the new Lancet paper. The new analysis both agrees with and builds upon that previous finding - and it should continue the discussion on the "worth" of faster door-to-balloon times that arose after the NEJM paper came out.

"The prior paper was an important observation but still left us with a question of 'why?'," says Nallamothu. "With this new analysis, we think we have a potential explanation that was previously overlooked. It suggests that our hard work in heart attack care has had an impact on patients, but it is just that we are taking care of different patients these days.

"Interventional cardiologists and teams routinely have to get out of bed at 3 a.m. and quickly get to the cath lab to treat a patient, so they want a real understanding of what rapid treatment is doing for patients," he continues. "The patients we're getting out of bed for these days, when approximately 90 percent of STEMI patients get pPCI, are very different from the ones we treated in 2006, when only about half of that number of STEMI patients received pPCI. And there's more we can do for them as the technologies and medications change. This kind of research helps us understand what the ultimate payoff is."


In addition to Nallamothu and Krumholz, the new paper's authors include Timothy P. Hofer, MD, MSc from the U-M Department of Internal Medicine as well as Sharon-Lise T. Normand, PhD, Yongfei Wang, MSc, John E. Brush, Jr, MD, John C. Messenger, MD, Elizabeth H. Bradley, PhD, and John S. Rumsfeld, MD, PhD. The study used data from the NCDR CathPCI Registry, co-sponsored by the American College of Cardiology (ACC) and the Society for Cardiovascular Angiography and Interventions (SCAI). Nallamothu and Hofer are members of the U-M Institute for Healthcare Policy and Innovation, and the VA Center for Clinical Management Research.The research was funded by grant HL105270-05 from the National Heart, Lung, and Blood Institute.

[Attachments] See images for this press release:
Paradox lost: Speedier heart attack treatment saves more lives after all, study suggests


First demonstration of anti-cancer activity for an IDH1 mutation inhibitor

Barcelona, Spain: A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced acute myeloid leukaemia (AML) with the IDH1 mutation. Professor Daniel Pollyea, M.D. will tell the 26th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, today (Wednesday) that early results from the phase 1 clinical trial of the drug AG-120, an oral, selective and potent inhibitor ...

Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs

Barcelona, Spain: Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs. Dr Ramaprasad Srinivasan, head of the Molecular Cancer Therapeutics Section, Urologic Oncology Branch, of the National Cancer Institute in Maryland, USA, will tell the 26th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, today (Wednesday) that the combination of bevacizumab and erlotinib produced ...

Galeterone shows activity in a variant form of castration-resistant prostate cancer

Barcelona, Spain: Results from a trial of the anti-cancer drug galeterone show that it is successful in lowering prostate-specific antigen (PSA) levels in men with a form of prostate cancer that is resistant to treatment with hormone therapy (castration-resistant prostate cancer or CRPC). Associate professor Mary-Ellen Taplin, of the Dana-Farber Cancer Institute, Boston, USA, will tell the 26th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, today (Wednesday) that galeterone was well tolerated by patients in the ARMOR2 trial, ...

Low vitamin D levels increase mortality

Low vitamin D levels increase mortality
VIDEO: New research from the University of Copenhagen and Copenhagen University Hospital shows that low blood vitamin D levels increase mortality. The study included 96,000 Danes and was recently published in... Click here for more information. Vitamin D deficiency is generally associated with an increased risk of poor bone health. However, recent studies have shown that low levels of this important vitamin also involve an increased risk of other diseases and higher mortality ...

The Lancet Psychiatry: Coping strategies therapy significantly improves dementia carers' mental health and quality of life

A brief coping strategies therapy which provides stress relief and emotional support for people caring for relatives with dementia can reduce depression and anxiety and improve wellbeing at no extra cost to standard care, new research published in The Lancet Psychiatry suggests. The study led by Gill Livingston, Professor of Psychiatry of Older People at University College London in the UK, found that family caregivers receiving the START (STrAtegies for RelaTives) programme were seven times less likely to develop clinically significant depression than those given usual ...

Songbirds help scientists develop cooling technique to safely map the human brain

A new diagnostic technique -- resulting from monitoring thousands of courtship calls from songbirds -- can be used to safely map the human brain during complex neurosurgery, according to research from Neuroscientists at NYU Langone Medical Center and elsewhere. The mapping process, first tested in zebra finches, involves gently placing a miniature electrical cooling device at different locations on a small region of the songbirds' brains. This slows down processing of complex neural behaviors, such as a birdsong or human speech. In a report prepared for the Society ...

Seniors draw on extra brainpower for shopping

Seniors draw on extra brainpower for shopping
DURHAM, N.C. -- Holiday shopping can be mentally exhausting for anyone. But a new Duke University study finds that older adults seem to need extra brainpower to make shopping decisions -- especially ones that rely on memory. The study appearing Nov. 19 in the Journal of Neuroscience suggests that older shoppers use an additional brain area to remember competing consumer products and choose the better one. "The study gives a bright picture, actually," said lead author Nichole Lighthall, a postdoctoral researcher in Roberto Cabeza's lab at Duke's Center for Cognitive ...

Cells' natural response to chronic protein misfolding may do more harm than good

Cells natural response to chronic protein misfolding may do more harm than good
LA JOLLA, CA--November 18, 2014--"Protein misfolding" diseases such as cystic fibrosis and Alzheimer's may be seriously exacerbated by the body's own response against that misfolding, according to a new study led by scientists at The Scripps Research Institute (TSRI). The researchers examined patient cells and animal models of several diseases that feature chronic protein misfolding and found that in each case, a cellular defense system against protein misfolding, called the "heat shock response," was overactive. Reducing its activity lessened the signs of disease and ...

Penn-led team prevents memory problems caused by sleep deprivation

Penn-led team prevents memory problems caused by sleep deprivation
Sleep is a critical period for memory consolidation, and most people don't get enough. Research has shown that even brief periods of sleep deprivation can lead to deficits in memory formation. In a new study, published in the Journal of Neuroscience, a team led by scientists from the University of Pennsylvania found that a particular set of cells in a small region of the brain are responsible for memory problems after sleep loss. By selectively increasing levels of a signaling molecule in these cells, the researchers prevented mice from having memory deficits. Robbert ...

Cedars-Sinai study of Lou Gehrig's disease shifts 'origin' focus to brain's motor neurons

LOS ANGELES (STRICTLY EMBARGOED UNTIL 5 P.M. EST on NOV. 11, 2014) - Lou Gehrig's disease, also known as amyotrophic lateral sclerosis, or ALS, might damage muscle-controlling nerve cells in the brain earlier in the disease process than previously known, according to research from the Cedars-Sinai Board of Governors Regenerative Medicine Institute. The findings, published in the Nov. 12 Journal of Neuroscience, could shift researchers' attention from the spinal cord to the brain's motor cortex as the disease's initial point of dysfunction. "In this study, we show the ...


Scientists model 'true prevalence' of COVID-19 throughout pandemic

New breakthrough to help immune systems in the fight against cancer

Through the thin-film glass, researchers spot a new liquid phase

Administering opioids to pregnant mice alters behavior and gene expression in offspring

Brain's 'memory center' needed to recognize image sequences but not single sights

Safety of second dose of mRNA COVID-19 vaccines after first-dose allergic reactions

Changes in disparities in access to care, health after Medicare eligibility

Use of high-risk medications among lonely older adults

65+ and lonely? Don't talk to your doctor about another prescription

Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose

Plant root-associated bacteria preferentially colonize their native host-plant roots

Rare inherited variants in previously unsuspected genes may confer significant risk for autism

International experts call for a unified public health response to NAFLD and NASH epidemic

International collaboration of scientists rewrite the rulebook of flowering plant genetics

Improving air quality reduces dementia risk, multiple studies suggest

Misplaced trust: When trust in science fosters pseudoscience

Two types of blood pressure meds prevent heart events equally, but side effects differ

New statement provides path to include ethnicity, ancestry, race in genomic research

Among effective antihypertensive drugs, less popular choice is slightly safer

Juicy past of favorite Okinawan fruit revealed

Anticipate a resurgence of respiratory viruses in young children

Anxiety, depression, burnout rising as college students prepare to return to campus

Goal-setting and positive parent-child relationships reduce risk of youth vaping

New research identifies cancer types with little survival improvements in adolescents and young adul

Oncotarget: Replication-stress sensitivity in breast cancer cells

Oncotarget: TERT and its binding protein: overexpression of GABPA/B in gliomas

Development of a novel technology to check body temperature with smartphone camera

The mechanics of puncture finally explained

Extreme heat, dry summers main cause of tree death in Colorado's subalpine forests

[] Paradox lost: Speedier heart attack treatment saves more lives after all, study suggests
Because more and sicker patients now get emergency angioplasty and stents, population-wide results look puzzling -- but new analysis clears confusion